Lalong urges laboratory scientists to be proactive in treatment of diseases
The Plateau State governor, Barr Simon Bako Lalong, has urged the Association of Medical Laboratory Scientists of Nigeria (AMLSN) to focus their responsibility on the production of vaccines and other biological used in testing and treatment of diseases.
The governor was represented by the permanent secretary in the ministry of health, Pharmacist Habila Gwatau, at the Hill Station Hotel’s conference hall, Jos.
Governor Lalong tasked AMLSN to investigate causes of diseases as well as provide solutions in terms of treatment and monitoring of same, especially in the era of evidence-based medicines, as the need for this cannot be overemphasized.
“We have inaugurated the Plateau state primary health care development agency to ensure qualitative health services are available to the majority of our rural populace, who live in the communities,” the governor stated.
He reminded that, as a result of the consistent outbreaks of Lassa fever in the state, “We trained health professionals, including medical laboratory scientists, to prepare them for better response to the emergency.
Governor Lalong stated that the federal government announced that it has gone into collaboration with the Baker Company to reactive the moribund human vaccines laboratories for local vaccines production in Nigeria.
In his welcome address, AMLSN’s chairman scientists and education committee in plateau state branch, Dr Salihu Aliyu Elayo, said, “Plateau state came together to brainstorm on topical issues to share research and diagnostic experiences and discuss on challenges affecting the profession with the view to proffering solutions to some of the challenges.”
According to him, it is hoped that each and every participant at this conference will listen attentively and contribute positively to the discussions for the progress of the country.
He said “participants will benefit from the theme and sub-themes of the conference where we shall contribute positive.”
The workshop explained that a bio-marker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacology response to a therapeutic intervention.
It revealed that “in cancer, a bio-marker refers to a substance process that is indicative of the presence of cancer in the body, either a molecules secreted by a tumor or it can be specific response,” he added.